A role of cis-dichlorodiammineplatinum(II) in squamous cell lung cancer

R. T. Eagan, T. R. Fleming, S. Frytak, E. T. Creagan, J. N. Ingle, L. K. Kvols

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

Forty-one patients with advanced squamous cell lung cancer and no prior chemotherapy were entered in a prospectively randomized trial comparing dianhydrogalactitol plus Adriamycin (DA) versus DA plus cis-dichloro-diammineplatinum (II) (DAP). The DAP regimen was superior to the DA regimen in regression rate (53% versus 27%), median regression duration (255 versus 122 days), median time to tumor progression (approximately 175 versus 58 days), and median survival time (185 versus 126 days). Patients who were > 60 years old responded particularly well to the DAP regimen and accounted for most of the survival advantage. Nausea, vomiting, and myelosuppression were more frequent and severe with the DAP regimen. This study seems to indicate a role of cis-dichlorodiammineplatinum(II) in patients with advanced squamous cell lung cancer. The particular advantage noted for older patients needs further evaluation.

Original languageEnglish (US)
Pages (from-to)87-91
Number of pages5
JournalCancer Treatment Reports
Volume64
Issue number1
StatePublished - Aug 18 1980

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A role of cis-dichlorodiammineplatinum(II) in squamous cell lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Eagan, R. T., Fleming, T. R., Frytak, S., Creagan, E. T., Ingle, J. N., & Kvols, L. K. (1980). A role of cis-dichlorodiammineplatinum(II) in squamous cell lung cancer. Cancer Treatment Reports, 64(1), 87-91.